Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?

Troubled since a miss in hidradenitis suppurativa last fall, Acelyrin’s izokibep succeeded in a psoriatic arthritis trial, but will the drug compete well against other IL-17 inhibitors?